Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: Rogaratinib (BAY1163877)|DRUG: Combination drug
Sponsor: Bayer